Bone Marrow Transplantation

Top Story

Mutation status predicts outcomes after HSCT in myelodysplastic syndrome, AML

September 22, 2016

Somatic mutations in ASXL1, RUNX1 and TP53 appeared independently associated with poor outcomes and shorter OS in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia, according to study results published in Journal of Clinical Oncology.

“Myelodysplastic syndrome (MDS) are myeloid neoplasms that range from conditions with a near-normal life expectancy to forms that are close to acute myeloid leukemia,” Marco G. Della Porta, MD, of Fondazione IRCCS Policlinico San Matteo in Pavia, Italy, and colleagues wrote. “Their clinical heterogeneity reflects different somatic mutations that cause clonal proliferation and evolution of myelodysplastic cells.”

Perspective

AACR report: Sustained federal commitment required to accelerate cancer research progress

September 20, 2016
Extraordinary therapeutic advances, a renewed bipartisan commitment to medical research and the launch of the national cancer moonshot initiative have reinforced the…

Biden announces steps to improve clinical trials under cancer moonshot

September 19, 2016
Vice President Joe Biden outlined a plan to improve the efficiency and transparency of the U.S. clinical research system as part of the national cancer moonshot…

Eight important updates in blood cancer treatment

September 16, 2016
September is designated as National Blood Cancer Awareness Month. In conjunction with the observation, HemOnc Today presents eight important updates in the treatment of…
CME

The Patient with Severe Leukocytosis

No commercial support for this activity.

Currently five tyrosine kinase inhibitors are available for use in patients with chronic myeloid leukemia (CML)…
More »
Video

VIDEO: Effort to systematize approach to medicine has ‘taken on a life of its own’

January 20, 2016
More »
Featured
At Issue: Breast Cancer Resource Center

At Issue: Breast Cancer Resource Center

CME

The Patient with Multiple Ecchymoses

No commercial support for this activity.

Glanzmann’s thrombasthenia is a rare, inherited bleeding disorder that results from a mutation in αIIbß3, an integrin…
More »
In the Journals Plus

Mutation status predicts outcomes after HSCT in myelodysplastic syndrome, AML

September 22, 2016
Somatic mutations in ASXL1, RUNX1 and TP53 appeared independently associated with poor outcomes and shorter OS in patients undergoing allogeneic…

Perspective

AACR report: Sustained federal commitment required to accelerate cancer research progress

September 20, 2016
Extraordinary therapeutic advances, a renewed bipartisan commitment to medical research and the launch of the national cancer moonshot initiative…

Biden announces steps to improve clinical trials under cancer moonshot

September 19, 2016
Vice President Joe Biden outlined a plan to improve the efficiency and transparency of the U.S. clinical research system as part of the national…

Eight important updates in blood cancer treatment

September 16, 2016
September is designated as National Blood Cancer Awareness Month. In conjunction with the observation, HemOnc Today presents eight important updates…

In the Journals Plus

Pretransplantation mogamulizumab increases risk for GVHD–related mortality

September 14, 2016
Receipt of mogamulizumab prior to allogeneic hematopoietic stem cell transplantation significantly increased risk for graft-versus-host…

City of Hope announces faculty appointments

September 10, 2016
Several clinicians have joined the faculty at City of Hope. Flavia Pichiorri , PhD, has been appointed associate professor in…

In the Journals Plus

Cord-blood transplantation may be preferable for patients with minimal residual disease

September 7, 2016
Patients with pretransplantation minimal residual disease achieved comparable outcomes after receipt of a hematopoietic cell transplantation from an…

Blue ribbon panel presents research road map for cancer moonshot initiative

September 7, 2016
The national cancer moonshot initiative’s blue ribbon panel delivered 10 recommendations to form a 5-year research blueprint to accelerate…

In the Journals Plus

Bendamustine-based salvage regimen induces responses in relapsed, refractory Hodgkin lymphoma

August 20, 2016
Salvage therapy with bendamustine, gemcitabine and vinorelbine induced complete response prior to autologous hematopoietic stem cell transplantation…

ASTRO Annual Meeting to reflect theme of ‘enhancing value, improving outcomes’

August 18, 2016
The American Society for Radiation Oncology will hold its annual meeting from Sept. 25 to 28 in Boston. More than 10,000 people are expected to…

More Headlines »
morganatic-roan